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Abstract
Background: The normobaric oxygen paradox states that a short exposure to normobaric hyperoxia followed by
rapid return to normoxia creates a condition of ‘relative hypoxia’ which stimulates erythropoietin (EPO) production.
Alterations in glutathione and reactive oxygen species (ROS) may be involved in this process. We tested the effects
of short-term hyperoxia on EPO levels and the microcirculation in critically ill patients.
Methods: In this prospective, observational study, 20 hemodynamically stable, mechanically ventilated patients with
inspired oxygen concentration (FiO2) ≤0.5 and PaO2/FiO2 ≥ 200 mmHg underwent a 2-hour exposure to hyperoxia
(FiO2 1.0). A further 20 patients acted as controls. Serum EPO was measured at baseline, 24 h and 48 h. Serum
glutathione (antioxidant) and ROS levels were assessed at baseline (t0), after 2 h of hyperoxia (t1) and 2 h after
returning to their baseline FiO2 (t2). The microvascular response to hyperoxia was assessed using sublingual
sidestream dark field videomicroscopy and thenar near-infrared spectroscopy with a vascular occlusion test.
Results: EPO increased within 48 h in patients exposed to hyperoxia from 16.1 [7.4–20.2] to 22.9 [14.1–37.2]
IU/L (p = 0.022). Serum ROS transiently increased at t1, and glutathione increased at t2. Early reductions in
microvascular density and perfusion were seen during hyperoxia (perfused small vessel density: 85% [95%
confidence interval 79–90] of baseline). The response after 2 h of hyperoxia exposure was heterogeneous.
Microvascular perfusion/density normalized upon returning to baseline FiO2.
Conclusions: A two-hour exposure to hyperoxia in critically ill patients was associated with a slight increase
in EPO levels within 48 h. Adequately controlled studies are needed to confirm the effect of short-term
hyperoxia on erythropoiesis.
Trial registration: ClinicalTrials.gov (www.clinicaltrials.gov), NCT02481843, registered 15th June 2015,
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Background
Anemia is a frequent problem in critically ill intensive
care patients [1]. Inhibition of erythropoietin (EPO)
production induced by inflammatory cytokines
contributes to the etiology of critical illness anemia
[2–4]. A diminished oxygen (O2) content due to
anemia or hypoxaemia is the physiologic stimulus for
EPO synthesis [5]. Reports suggest that a sudden de-
crease in tissue O2 levels after a short-term exposure
to normobaric hyperoxia can stimulate EPO synthesis
by producing a state of “relative” hypoxia (normobaric
oxygen paradox, NOP) [6, 7]. However, studies are
needed to demonstrate the effectiveness of this
procedure, to define the optimal dose and frequency
of exposure [8], and to confirm the safety of transient
exposure to hyperoxia in ICU patients. Hyperoxia
induces oxidative damage to various organs [9], cor-
onary and systemic vasoconstriction [10] with a fall
in cardiac output [11], and a possible decrease in re-
gional O2 delivery [12]. Exposure to arterial hyperoxia
is also associated with higher mortality in certain ICU
patient subsets [13].
We aimed to test the effectiveness of the NOP on in-
creasing serum EPO levels in critically ill patients. Sec-
ondly, we explored the safety of hyperoxia exposure by
evaluating the microcirculatory response to hyperoxia
and the effects upon circulating levels of nitric oxide
(NO), reactive O2 species (ROS) and the antioxidant,
glutathione (GSH).
Methods
This prospective, non-randomized study was approved
by the Institutional Review Board of the Azienda Ospe-
daliera Universitaria Ospedali Riuniti of Ancona, Italy
(Protocol nr. 212638; NCT02481843 www.clinicaltrials.-
gov). Written informed consent was obtained from the
enrolled patients or their next of kin. Adult (≥18-year
old) patients admitted to the 12-bed medical-surgical
ICU of Azienda Ospedaliera Universitaria Ospedali Riu-
niti of Ancona, Italy between April 2013 and March
2015 and requiring mechanical ventilation with an in-
spired O2 fraction (FiO2) ≤0.5 and PaO2/FiO2 ≥
200 mmHg were eligible to participate. Exclusion criteria
were: hemoglobin (Hb) <9 g/dL, acute bleeding or blood
transfusion during the study period; surgical interven-
tions during the study period; acute or chronic renal
failure; hemodynamic instability; chronic obstructive
pulmonary disease; pregnancy; factors impeding evalu-
ation of the sublingual microcirculation (oral surgery or
maxillo-facial trauma). In all patients, blood pressure
was monitored with an arterial catheter. Sedation and
analgesia, fluids and vasopressors were provided accor-
ding to individual needs.
Interventions
Forty patients were enrolled in total and were allocated
in the hyperoxia or control group using a before-after
method. The first 20 patients (hyperoxia group) under-
went a 2-hour period of normobaric hyperoxia (FiO2
1.0), according to the protocol applied by Balestra et al.
[6]. No variation in FiO2 was applied to the last 20 pa-
tients (control group). All patients were enrolled in the
morning and hyperoxia was performed between 10.00
and 14.00 h to minimize variability due to the circadian
rhythm of EPO production. No variations to sedation or
vasopressor dosing or ventilator settings were applied
during the study period.
Measurements
On the study day, measurements were taken at baseline
(t0), after 2 h of breathing 1.0 FiO2 (hyperoxia, t1) and 2 h
after returning to baseline FiO2 (t2). Measures included
body temperature, heart rate (HR), mean arterial pressure
(MAP), arterial and central venous blood gases, arterial
lactate, evaluation of the sublingual microcirculation and
peripheral microvascular (StO2) oxygenation. The same
measures were performed in the control group but with
no period of hyperoxia. Serum EPO, reticulocyte count,
Hb and hematocrit were measured at 8 am in all patients
on the study day, and at 24 and 48 h.
Microcirculation assessment
The sublingual microcirculation was evaluated at five
different sites using sidestream dark field (SDF) videomi-
croscopy (Microscan, Microvision Medical, Amsterdam,
NL), as previously described [14–17]. Three images per
time-point were analyzed using the Automated Vascular
Analysis software (Microvision Medical BV). Total vessel
density (TVD), perfused vessel density (PVD), De Backer
score, proportion of perfused vessels (PPV), microcircu-
latory flow index (MFI), flow heterogeneity index (FHI)
and blood flow velocity (BFV) were calculated in small
or medium vessels (diameter ≤ or >20 μm, respectively)
[16, 18]. Continuous video recording was also performed
for ≥2 min on one site during the change in FiO2 (either
start or end of hyperoxia) to evaluate the early microcir-
culatory response. Video clips of 10 s’ duration (two per
time point) corresponding to before (baseline or 2 h
FiO2 1.0) and after (2 min FiO2 1.0 or 2 min after
returning to baseline FiO2) the change in FiO2 were
selected and subsequently analyzed.
Near-infrared spectroscopy (NIRS) (InSpectra™ Model
650; Hutchinson Technology Inc., Hutchinson, MN,
USA) with a 15 mm-sized probe was used to measure
microvascular oxygen saturation (StO2) and tissue Hb
index (THI) [19] on the thenar eminence at baseline and
during a vascular occlusion test [16, 20]. The StO2
downslope (%/minute) was calculated as an index of O2
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consumption, while the StO2 upslope (%/minute) and the
area under the curve (AUC) of the hyperemic response
were obtained to assess microvascular reactivity [20].
Immunoassays
In the first 12 patients in each group, arterial blood
samples (10 mL) were taken at baseline, t1 and t2 and
immediately centrifuged; plasma and serum were stored
at −70 °C. A marker of NO production was measured as
plasma nitrite/nitrate using a Nitric Oxide Colorimetric
Detection Kit (Cat. No. K023-H1, Arbor Assays, Ann
Arbor, MI, USA) while GSH levels were measured using
a Glutathione Colorimetric Detection Kit (Cat. No.
K006-H1 - Arbor Assays) following the manufacturer’s
instructions. High Reactive Oxygen Species (hROS)
levels were determined by hydroxyphenyl fluorescein
(Cell Technology Inc, Mountain View, CA, USA), which
selectively detects hydroxyl radical (●OH) and peroxyni-
trite (ONOO−) [21]. Immunoassays could not be
performed in all patients for economic reasons.
Statistical analysis
This was performed using GraphPad Prism Version 6
(GraphPad Software, La Jolla, CA, USA). Normality of dis-
tribution was checked using the Kolmogorov-Smirnov
test. The data were expressed as mean ± standard devi-
ation (SD) for normally distributed variables or median
[1st-3rd quartiles] for non-normally distributed variables.
One-way analysis of variance (ANOVA) for repeated mea-
sures with Bonferroni post-hoc testing (or Friedman’s test
with Dunn’s multiple comparison test for non-normally
distributed variables) was used to evaluate changes over
time in the same group. For normally distributed vari-
ables, the two-way ANOVA for repeated measures with
Bonferroni post-hoc testing was used to evaluate differ-
ences between the groups. For non-normally distributed
variables, the Mann-Whitney U test was applied to evalu-
ate differences between the two groups at the same time-
point. Spearman correlation coefficient was calculated to
assess correlations between variables. The alpha level of
significance was set a priori at 0.05.
Results
A total of 791 patients was screened during the 2-year
study period. Of these, 617 patients were excluded be-
cause they did not meet the predefined inclusion criteria
or had exclusion criteria; 105 patients were excluded as
already enrolled in another study; 24 patients denied
consent to participation in the study; 45 patients were
not enrolled due to the unavailability of the investigators
or SDF/NIRS devices. Median age was 74 [53–81] years
in the hyperoxia group and 65 [56–73] years in the con-
trol group. The male:female ratio was 10:10 and 14:6 in
the hyperoxia and control groups, respectively.
Admission diagnoses were neurological (hyperoxia
group: 4 patients, controls: 12), polytrauma (hyperoxia:
5, controls: 7), post-cardiac arrest (hyperoxia: 7, controls:
1) and sepsis (hyperoxia: 3, none in the control group).
The Sequential Organ Failure Assessment (SOFA) score
was 8.5 [6.2–10] and 8 [6–9] in the hyperoxia and
control groups, respectively.
Hemodynamic and blood gas data
The PaO2 increased to >400 mmHg during hyperoxia. A
significant decrease in MAP (p < 0.01 versus t1) and in-
crease in HR (p < 0.05 versus t0 and t1) were found at t2
in the hyperoxia group. Central venous O2 saturation
(ScvO2) increased in the hyperoxia group at t1 (p < 0.001
versus t0 and t2). Arterial lactate levels increased in the
hyperoxia group and were higher than those seen in the
control group at t1 and t2 (Table 1).
Effects on erythropoiesis
EPO levels rose in the hyperoxia group (p < 0.05) and
were significantly higher at 48 h compared to baseline
(p < 0.05). No changes were seen in the control group.
The reticulocyte count and Hb levels fell over time in
both groups (Table 2).
Effects on the sublingual microcirculation
Continuous microcirculatory assessment of the same site
during changes in the FiO2 showed that the first 2 min of
hyperoxia were associated with an early and consist-
ent reduction in TVD (87% [95% confidence interval
(CI) 82–91] of baseline for small vessels), PVD (85%
[79–90] of baseline for small vessels) and PPV (97%
[96–99] of baseline for small vessels) (Fig. 1). When
compared to measures taken after breathing an FiO2
of 1.0 for 2 h, these parameters increased on return
to the baseline FiO2 (TVD: 107% [100–114], PVD:
109% [102–117], PPV: 102% [100–103] (Fig. 1).
Evaluation of the microcirculation at 2-hour intervals
showed a more heterogeneous response. A trend was
seen towards a reduction in the De Backer score, TVD
and PVD for small vessels at t1, with normalization at t2
(Table 3). The variation in TVD after 2 h hyperoxia (t1-
t0) was inversely correlated with the change seen 2 h
after return to the baseline FiO2 (t2-t1) (r = −0.52 [95%
CI −0.78, −0.10]). The microcirculation remained stable
over time in the control group, which showed a signifi-
cantly higher De Backer score, TVD and PVD for small
and medium vessels as compared to the hyperoxia group
at all time-points (Table 3).
NIRS variables
The StO2 value was not affected by changes in FiO2. The
gradient of the StO2 downslope was however significantly
increased at t2 in the hyperoxia group (p < 0.01 versus t1)
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implying increased O2 extraction rate, although no
significant difference was found with the control
group. The StO2 upslope, area under the curve and
THI did not show any significant change over time in
the hyperoxia group compared to controls. All NIRS
parameters remained stable in the control group and
no differences were found between the two groups at
any time-point (Table 3).
NO, ROS and GSH
The percentage variations of ROS and GSH in the
hyperoxia group are shown in Fig. 2. ROS increased to
Table 1 Variations in hemodynamics and blood gas parameters under hyperoxia and after the return to baseline FiO2
t0 t1 t2 p (time)a p (interaction)b
Heart Rate (bpm) 0.813
Hyperoxia 70 ± 20 71 ± 22 77 ± 22##‡ 0.008
Controls 67 ± 19 66 ± 19 72 ± 25 0.086
Mean Arterial Pressure (mmHg) -
Hyperoxia 86 [70–91] 87 [81–97] 83 [72–87]* 0.008
Controls 87 [79–101] 88 [84–97] 85 [81–92] 0.462
Body temperature (°C) 0.176
Hyperoxia 36.1 ± 1.1 36.3 ± 0.9 36.3 ± 1.1* 0.407
Controls 36.7 ± 0.8 36.7 ± 0.9 37.1 ± 0.8#‡ 0.010
PaO2 (mmHg) <0.001
Hyperoxia 108 ± 35 433 ± 109###*** 111 ± 26‡‡‡ <0.001
Controls 118 ± 33 119 ± 28 115 ± 33 0.622
SaO2 (%) -
Hyperoxia 99.7 [98.9–100] 100[100–100]###*** 99.8 [99.1–100]‡‡ <0.001
Controls 100 [99.6–100] 99.9 [99.5–100] 99.8 [99.5–100] 0.863
PaO2/FiO2 (mmHg) <0.001
Hyperoxia 290 ± 93 435 ± 111###*** 287 ± 82‡‡‡ <0.001
Controls 314 ± 108 315 ± 93 303 ± 99 0.330
ScvO2 (%) -
Hyperoxia 79 [70–83] 86 [74–90]### 76 [72–81]‡‡‡ <0.001
Controls 82 [74–84] 80 [75–85] 79 [75–84] 0.838
pH 0.696
Hyperoxia 7.48 ± 0.07 7.49 ± 0.07 7.48 ± 0.07 0.516
Controls 7.45 ± 0.06 7.45 ± 0.05 7.45 ± 0.06 0.966
PaCO2 (mmHg) -
Hyperoxia 38 [36–42] 39 [34–42] 39 [36–42] 0.826
Controls 38 [34–42] 39 [35–43] 41 [35–42] 0.145
Base excess (mmol/L) 0.971
Hyperoxia 5.0 ± 5.2 5.3 ± 5.3 5.6 ± 4.9 0.430
Controls 2.9 ± 3.8 3.1 ± 4.1 3.3 ± 3.6 0.288
Lactate (mmol/L) -
Hyperoxia 1.1 [0.7–1.5] 1.2 [1.1–2.0]** 1.3 [1.0–1.8]* 0.037
Controls 0.9 [0.7–1.2] 0.9 [0.7–1.2] 0.9 [0.7–1.2] 0.616
Data are expressed as mean ± standard deviation or median [1st-3rd quartile], as appropriate (t0): baseline; (t1): 2 h 1.0 FiO2; (t2): 2 h after the return to
baseline FiO2
a Overall effect of time on the variance in each group. One-way ANOVA for repeated measures with Bonferroni’s post hoc test or Friedman test with Dunn’s test
for multiple comparisons, as appropriate
b Test of interaction between time and groups. Two-way ANOVA for repeated measures. This was applicable only to normally distributed variables
*p < 0.05, **p < 0.01, ***p < 0.001 versus controls (same time point); two-way ANOVA for repeated measures with Bonferroni post-hoc test or Mann-Whitney test,
as appropriate
#p < 0.05, ##p < 0.01, ###p < 0.001 versus t0; ‡p < 0.05, ‡‡p < 0.01, ‡‡‡p < 0.001 versus t1; One-way ANOVA for repeated measures with Bonferroni’s post hoc test or
Friedman test with Dunn’s test for multiple comparisons, as appropriate
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Table 2 Variations in erythropoietin, reticulocyte count, haemoglobin and haematocrit in the two groups
Baseline 24 h 48 h p (time)a p (interaction)b
Erythropoietin (IU/L) -
Hyperoxia 16.1 [7.4–20.2] 20.1 [10.7–31.2] 22.9 [14.1–37.2]# 0.022
Controls 12.8 [7.3–22.2] 14.9 [9.2–18.6] 14.8 [7.9–24.8] 0.692
Reticulocytes (*103/mm3) -
Hyperoxia 55.9 [39.4–67.4] 47.3 [33.1–62.2]## 46.2 [29.8–66.2] 0.010
Controls 60.2 [46.3–78.7] 52.5 [42.9–65.9] 50.7 [44.1–64.5]# 0.027
Hemoglobin (g/dL) 0.601
Hyperoxia 10.7 ± 1.4 10.2 ± 1.3 10.1 ± 1.3# 0.013
Controls 11.7 ± 2.0 11.3 ± 1.8 11.3 ± 1.7 0.027
Hematocrit (%) 0.053
Hyperoxia 32 ± 6 31 ± 6 30 ± 6#* 0.029
Controls 34 ± 8 34 ± 8 34 ± 8 0.675
Data are expressed as mean ± standard deviation or median [1st-3rd quartile], as appropriate
a Overall effect of time on the variance in each group. One-way ANOVA for repeated measures with Bonferroni’s post hoc test or Friedman test with Dunn’s test
for multiple comparisons, as appropriate
b Test of interaction between time and groups. Two-way ANOVA for repeated measures. This was applicable only to normally distributed variables
*p < 0.05 versus controls (same time point); two-way ANOVA for repeated measures with Bonferroni post-hoc test
Fig. 1 Early microcirculatory response to acute variations in the FiO2. a: Sidestream Dark Field imaging of the same site of sublingual
microcirculation in one patient before (FiO2 0.5) and after 2 min of exposure to hyperoxia (2 min FiO2 1.0). Stars indicate regions of microvascular
de-recruitment. b and c: Individual and mean (SD) changes in perfused vessel density (b) and proportion of perfused vessels (c) during acute
variations in the FiO2 in the hyperoxia group (n = 20). The same region of the sublingual mucosa was assessed continuously at each time point
(start hyperoxia and end hyperoxia) for at least 2 min . *p < 0.05, ***p < 0.001, paired t-test
Donati et al. BMC Anesthesiology  (2017) 17:49 Page 5 of 10
Table 3 Sublingual and peripheral microvascular changes after a 2-hour exposure to hyperoxia and 2 h after return to baseline FiO2
t0 t1 t2 p (time)a p (interaction)b
TVD small (mm/mm2) -
Hyperoxia 18.5 [16.5–21.6]** 16.4 [14.6–21.6]** 19.3 [18.2–21.3]‡* 0.035
Controls 21.7 [20.0–23.8] 22.2 [18.8–24.3] 21.0 [19.8–23.7] 0.705
TVD medium (mm/mm2) -
Hyperoxia 0.9 [0.4–1.6] 0.5 [0.4–0.9]** 0.7 [0.3–1.3] 0.268
Controls 1.2 [0.8–1.8] 1.0 [0.7–1.8] 1.1 [0.6–1.7] 0.861
PVD small (mm/mm2) -
Hyperoxia 17.4 [16.3–20.8]** 15.4 [13.2–20.3]** 18.4 [17.1–19.9]* 0.058
Controls 20.1 [18.9–22.6] 21.0 [18.0–23.3] 20.0 [18.5–22.9] 0.549
PVD medium (mm/mm2) 0.178
Hyperoxia 0.9 ± 0.6 0.6 ± 0.5* 0.8 ± 0.6 0.142
Controls 1.2 ± 0.6 1.2 ± 0.6 1.1 ± 0.7 0.851
De Backer score (n/mm) -
Hyperoxia 11.2 [9.9–13.2]** 9.7 [8.8–13.2]** 11.8 [10.0–13.4]‡** 0.019
Controls 14.5 [12.0–15.8] 14.1 [11.6–15.8] 14.1 [12.7–16] 0.951
MFI small (AU) -
Hyperoxia 2.74 [2.50–2.90] 2.67 [2.50–2.90] 2.75 [2.52–2.92] 0.713
Controls 2.67 [2.44–2.90] 2.75 [2.60–3.00] 2.79 [2.67–2.98] 0.099
PPV small (%) 0.223
Hyperoxia 96 ± 3 94 ± 4 95 ± 3 0.149
Controls 94 ± 4 95 ± 3 95 ± 4 0.396
FHI small (AU) -
Hyperoxia 0.14 [0.08–0.21] 0.18 [0.09–0.30]* 0.10 [0.02–0.20] 0.551
Controls 0.09 [0.02–0.19] 0.09 [0.00–0.18] 0.09 [0.00–0.18] 0.290
BFV (μm/s) 0.631
Hyperoxia 497 ± 63 489 ± 81 502 ± 45 0.741
Controls 520 ± 56 519 ± 54 531 ± 65 0.537
StO2 (%) 0.655
Hyperoxia 80 ± 8 82 ± 8 82 ± 7 0.261
Controls 81 ± 9 81 ± 8 82 ± 9 0.824
StO2 downslope (%/min) -
Hyperoxia −7.9 [−9.1, −7.0] −7.7 [−9.3, −6.8] −9.4 [−11.0, −7.9]‡ 0.003
Controls −8.1 [−9.7, −6.8] −7.9 [−10.1, −7.0] −8.6 [−9.9, −6.9] 0.212
StO2 upslope (%/min) -
Hyperoxia 133 [98–243] 194 [145–274] 192 [140–244] 0.101
Controls 194 [150–228] 193 [139–262] 219 [132–263] 0.247
StO2 area under the curve (%*min) 0.284
Hyperoxia 14.6 ± 8.8 18.0 ± 11.8 13.2 ± 7.6 0.066
Controls 20.3 ± 15.1 19.8 ± 14.7 18.3 ± 13.3 0.660
THI (AU) 0.884
Hyperoxia 11.0 ± 3.2 11.4 ± 3.8 11.8 ± 3.2 0.374
Controls 12.6 ± 2.2 12.7 ± 3.5 13.0 ± 3.1 0.801
Data are expressed as mean ± standard deviation or median [1st-3rd quartile], as appropriate. (t0): baseline; (t1): 2 h 1.0 FiO2; (t2): 2 h after the return to baseline
FiO2. TVD total vessel density, PVD perfused vessel density, PPV proportion of perfused vessels, MFI microvascular flow index, FHI flow heterogeneity index, BFV blood
flow velocity
a Overall effect of time on the variance in each group. One-way ANOVA for repeated measures with Bonferroni’s post hoc test or Friedman test with Dunn’s test for
multiple comparisons, as appropriate
b Test of interaction between time and groups. Two-way ANOVA for repeated measures. This was applicable only to normally distributed variables
*p < 0.05, **p < 0.01 versus controls (same time point); two-way ANOVA for repeated measures with Bonferroni post-hoc test or Mann-Whitney test, as appropriate
‡p < 0.05 versus t1; Friedman test with Dunn’s test for multiple comparisons, as appropriate
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111% [95% CI 104–117] of baseline at t1 (p < 0.05 versus
t0), and decreased to 97% [91–104] of baseline at t2 (p <
0.01 versus t1). GSH did not change at t1 (98% [92–103]
of baseline) but increased to 103% [99–107] of baseline
at t2 (p < 0.05 versus t1). NO did not change significantly
over time in either group (Table 4). No correlation was
found between changes in nitrite/nitrate and changes in
sublingual microvascular parameters.
Discussion
In this prospective observational study on 40 critically ill
patients within different disease categories, a single 2-
hour exposure to normobaric hyperoxia was associated
with a slight increase in serum EPO levels over the fol-
lowing 48 h, despite wide inter-individual variability in
the response observed. An initial decrease in micro-
vascular perfusion was seen during hyperoxia, followed
by normalization on returning to the baseline FiO2.
Serum ROS levels were elevated after hyperoxia, while
the return to the baseline FiO2 was associated with an
increase in GSH and normalization of ROS levels.
Intermittent hyperoxia can stimulate erythropoiesis in
healthy volunteers and in various patient categories [6,
7, 22, 23], although other reports have questioned the
existence of a NOP [24]. Mechanisms underlying the
NOP may involve regulation of Hypoxia-Inducible Fac-
tor 1-alpha (HIF-1α) expression. During normoxia, HIF-
1α undergoes ubiquitination by the Von Hippel Lindau
tumor suppressor and degradation into the proteasome.
This process is mediated by the oxidized form of gluta-
thione (GSSG). Under hypoxia, the GSH-GSSG ratio in-
creases, thus limiting the inactivation of HIF-1α, which
can induce expression of the EPO gene. The increase in
ROS during hyperoxia induces de novo synthesis of
GSH. When returning to normoxia, the increased pro-
duction of GSH, together with the reduction of GSSG to
GSH, creates a “surplus” of GSH that enhances the in-
activation of HIF-1α [6]. Our findings are consistent
with this theory: serum ROS levels increased after 2 h of
hyperoxia, while GSH levels were elevated 2 h after
returning to the baseline FiO2. This variation in GSH
levels may be able to modulate the activity of HIF-1α
and EPO production.
Several factors may account for the inter-individual
variability observed in the NOP response. Arterial hyper-
oxia (PaO2 > 100 mmHg) was present at baseline in 60%
of patients in the hyperoxia group; this may have had
either a positive (enhanced induction of GSH synthesis)
or negative (higher ROS levels) impact on the EPO
response. The two groups were also unbalanced for
admission diagnosis so definitive conclusions cannot be
drawn. Importantly, baseline Hb levels tended to be
lower in the hyperoxia group: this could in itself act as a
stimulus for EPO synthesis independent of exposure to
hyperoxia.
As EPO secretion normally follows an individual
circadian rhythm of production, individual matching of
the circadian rhythm is needed to detect an increase in
EPO levels at a specific time of the day [8]. This could
be particularly important in ICU patients where the
normal circadian rhythm of hormone production is
frequently abolished due to their underlying illness as
well as sedation and disturbances in the sleep-wake cycle
[25]. We measured EPO levels at 08.00 h each morning
in all patients to limit the impact of this source of
variability.
The ideal “dose” of O2 for triggering the NOP is poorly
described. An excessive increase in ROS (such as that in-
duced by hyperbaric hyperoxia) may suppress rather than
stimulate EPO production [6]. An FiO2 of 1.0 may not
represent optimal dosing for all patients and could have
produced varying effects. Repeated rather than single
exposures may perhaps be more effective [8].
Arterial hyperoxia causes vasoconstriction, thus reducing
tissue perfusion [11, 26]. This cannot be part of an evolu-
tionary innate response as exposure to high concentrations
Fig. 2 Individual and mean (SD) changes in serum ROS (a) and GSH (b) levels in the hyperoxia group (n = 12), expressed as percentage of
baseline values. *p < 0.05, **p < 0.01, one-way ANOVA for repeated measures with Bonferroni’s post hoc test
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of inspired oxygen can only be traced back to the relatively
modern era. Arterial hyperoxia must therefore represent a
purely iatrogenic ‘insult’; the ensuing physiological response
(vasoconstriction) to the resulting tissue hyperoxia may re-
produce adaptive efforts to match O2 supply to reduced
cellular metabolic needs seen in pathological states such as
sepsis where tissue oxygen tensions rise [27]. The corollary
of reducing oxygen supply in conditions of relative tissue
oxygen excess is a blunting of the increase in ROS produc-
tion, thereby attenuating toxicity.
Mechanisms underlying this response may involve a
down-regulation of the adenosine pathway [28] or modu-
lation of the ROS-mediated prostaglandin and NO path-
ways [29] with reduced NO bioavailability [30]. In our
study, hyperoxia led to an early decrease in microcircula-
tory vessel density and perfusion after 2 min of exposure.
These alterations persisted after 2 h in some patients,
while others showed similar or even increased vessel
densities as compared with baseline levels. No reduction
in plasma NO levels was seen after 2 h hyperoxia, which
may reflect the variability observed in microvascular
perfusion. An undetected short-lived derangement in the
NO pathway may at least partly explain the early microcir-
culatory alterations observed. Our results suggest that the
vasoconstrictor response was more pronounced during an
acute increase in arterial PaO2 rather than after a more
sustained exposure. Of note, continuous monitoring of
the microcirculation in the same region of sublingual
mucosa is likely to be more sensitive in detecting even
minute variations in vessel density compared to intermit-
tent measurements, as it excludes any variability related to
the random selection of different areas, albeit averaged
over three samples [31, 32].
Microvascular density and perfusion normalized after
the return to the baseline FiO2. This was associated with
a decrease in MAP and an increase in HR after 2 h ,
suggesting a decrease in systemic vascular resistance.
The increased gradient in the StO2 downslope at 2 h
after returning to baseline FiO2 indicates a higher re-
gional O2 extraction rate. This likely reflects an increase
in local perfusion and O2 consumption in this phase.
Notably, the microvascular response at 2 h after return
to normoxia was inversely related to the variations
observed after 2 h of hyperoxia. In other words, those
patients who did not demonstrate hyperoxia-induced
vasoconstriction tended to show an unaltered or even
decreased vessel density at return to baseline FiO2.
Several factors including baseline PaO2 and ROS levels,
factors affecting vascular tone, or an underlying micro-
vascular/endothelial dysfunction may determine this
“non-physiological” response. In healthy volunteers nor-
mobaric hyperoxia induced a reduction in the estimated
muscle O2 consumption with slower StO2 drop during
the VOT [10]. In our study, the StO2 downslope was
unaltered after 2 h of hyperoxia, suggesting no apparent
effect on muscle O2 consumption, which seems in
contrast to the increased ScvO2. It should be taken into
account that the response of the peripheral skeletal
muscle circulation may not always reflect the response
of other organs in the critically ill. Microvascular mecha-
nisms of regulation and adaptation may vary between
different capillary beds and may be impaired in a hetero-
geneous manner during critical illness. Sedation or
vasopressors in ICU patients may influence tissue O2 re-
quirements and extraction rate in the peripheral skeletal
muscle circulation. Differences in the study protocol and
time of exposure to hyperoxia may also contribute to
the discrepant results.
Our study has several limitations. First, the non-
randomized, non-blinded design of the study, together
with the relatively small sample size, precludes drawing
definitive conclusions. Second, we studied a necessarily
heterogenous critically ill patient population, although
we tried to standardize both the patients and their status
Table 4 Changes in nitrite/nitrate, GSH and ROS after a 2-hour exposure to hyperoxia and 2 h after return to baseline FiO2
t0 t1 t2 p (time)a p (interaction)b
Nitrite/nitrate (μM) 0.378
Hyperoxia (n = 12) 41 ± 17 45 ± 21 43 ± 18 0.301
Controls (n = 12) 51 ± 18 55 ± 16 59 ± 14 0.198
GSH (μM) -
Hyperoxia (n = 12) 2.21 [2.12–2.28] 2.17 [2.09–2.25] 2.24 [2.20–2.39] 0.114
Controls (n = 12) 2.19 [2.12–2.33] 2.18 [2.15–2.23] 2.23 [2.17–2.28] 0.273
ROS (RFU) -
Hyperoxia (n = 12) 2915 [1196–6537] 3109 [1348–6961] 3061 [1261–5841] 0.046
Controls (n = 12) 1773 [1070–3018] 2024 [1135–3069] 1841 [1066–3058] 0.338
These analyses were restricted to the 12 patients per group. Data are expressed as mean ± standard deviation or median [1st-3rd quartile], as appropriate. (t0):
baseline; (t1): 2 h 1.0 FiO2; (t2): 2 h after return to baseline FiO2. RFU relative fluorescence units
a Overall effect of time on the variance in each group. One-way ANOVA for repeated measures with Bonferroni’s post hoc test or Friedman test with Dunn’s test
for multiple comparisons, as appropriate
b Test of interaction between time and groups. Two-way ANOVA for repeated measures. This was applicable only to normally distributed variables
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(e.g. cardiorespiratory stability) as much as possible. Third,
baseline differences in Hb between the two groups may be
responsible for different changes in EPO levels, irrespect-
ive of the exposure to hyperoxia. In addition, we cannot
exclude that differences in other parameters between the
two groups (e.g. lower body temperature in the hyperoxia
group) influenced microvascular perfusion and the
changes detected. Fourth, the observed increase in EPO
levels may not have been sufficient to induce a significant
increase in erythropoiesis. The 48-hour observational
period may have been too short to detect an increase in
reticulocyte count and Hb after the exposure to hyperoxia.
We focussed upon EPO production as numerous
confounding factors may have influenced Hb levels over
this time period including hemodilution due to fluid infu-
sion, anemia of inflammation, repeated blood sampling,
and other blood losses. Fifth, NO, ROS and GSH were
measured only in 60% of the study population. Lastly,
cardiac output and systemic vascular resistance were not
measured in this stable population. As MAP was stable
over the course of our study despite the local vasocon-
strictor response, we speculate that cardiac output was
reduced after 2 h of hyperoxia.
Conclusions
A two-hour exposure to normobaric hyperoxia was asso-
ciated with a slight increase in serum EPO levels within
48 h in critically ill patients. Mechanisms responsible for
the stimulation of erythropoiesis may include an enhanced
production of GSH induced by an increase in ROS. This
enhanced oxidative stress was followed by normalization
2 h after returning to baseline levels of FiO2. An early
vasoconstrictor response was observed at the microcircu-
latory level under hyperoxia. After 2 h , the response was
heterogeneous between different patients, but normalized
on returning to the baseline FiO2.
The findings of this pilot study encourage further
exploration of the NOP as a means of stimulating erythro-
poiesis during critical illness. However, adequately
controlled studies are needed to isolate the effect of short-
term hyperoxia on EPO production independently of pos-
sible confounding factors such as baseline Hb levels or the
patient’s underlying disease. Potential dangers of excessive
O2 exposure must also be considered, specifically en-
hanced oxidative stress and short-term alterations in
microvascular perfusion. Further investigations should
clarify the time course of the microvascular response and
recovery under hyperoxia in critically ill patients and iden-
tify any factors potentially influencing this response.
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